Faculty

David Shoultz

Affiliate Professor, Epidemiology

206-395-8752

Education

MBA Seattle University, 2012
PhD Epidemiology, University of Washington, 1997
MS Epidemiology, University of Washington, 1995
BSN University of Washington, 1991

Contact

206-395-8752

Seattle, WA 98195

Bio

Dr. David Shoultz is the inaugural Chief Scientific Officer (CSO) at the Myeloproliferative Neoplasm (MPN) Research Foundation.  He was appointed to this role in January 2025.  The mission of MPN Research Foundation is to stimulate original research in pursuit of new treatments, and eventually a cure, for the blood cancers essential thrombocythemia, polycythemia vera, and myelofibrosis, known collectively as MPN. Through a combination of investing in innovative research, advocating for the patient voice, and convening the global MPN community, the MPN Research Foundation brings together patients, researchers, and industry around the common goal of realizing new treatment options and, ultimately, cures for MPNs.


Prior to joining the MPN Research Foundation, David had most recently founded Monod Bio with Drs. Daniel Silva Manzano and Alfredo Quijano Rubio.  The Company spun out of the laboratory of UW Professor of Biochemistry and Institute for Protein Design (IPD) founder Dr. David Baker in 2021; Dr. Baker was awarded the Nobel Prize for Chemistry in 2024. Before founding Monod Bio, David held multiple positions of increasing responsibility at biotech, pharmaceutical, and life sciences companies.  In addition, he held significant leadership positions in global health product development at the Bill & Melinda Gates Foundation and PATH.  At PATH, David was the Global Program Leader for the Drug Development Program.

David received his bachelor’s degree, M.S., and Ph.D. from the University of Washington in Seattle. His MBA is from the Albers School of Business & Economics at Seattle University, where he was previously a faculty member in the Executive MBA Program. He has been on the Affiliate Faculty at the University of Washington in the departments of Epidemiology and Global Health for more than twenty (20) years, has advised students, given guest lectures, and designed and taught courses on global health and epidemiology.  He was also a member of the faculty at the Seattle University School of Business & Economics for many years; there he advised students and taught courses on strategy, operations, and health.

David's expertise includes the development of drugs, diagnostics and vaccines.  Beyond MPN, David has a special interest in other hematologic malignancies and cancers, and in infectious diseases - including those of importance in low and middle income countries (LMIC). David currently teaches courses on epidemiology in the Health Informatics and Health Information Management (HIHIM) and Masters of Health Administration (MHA) Programs at the University of Washington.

Research Interests

I am interested in global health product discovery, development, and delivery. I am also interested in innovative finance for global health product development. I am eager to collaborate with other faculty members and am available to work with master’s and doctoral students who share my interests and commitment to global health product development.

Recent Publications (PubMed)

Vital lessons from struggling partnerships and potential partnerships: an international study with leaders across the health sector.
(2024 Nov 26)
BMC Health Serv Res 24(1): 1470
Zwisler G, Sauer CM, Shoultz D

De Novo Human Angiotensin-Converting Enzyme 2 Decoy NL-CVX1 Protects Mice From Severe Disease After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
(2023 Sep 15)
J Infect Dis 228(6): 723-733
Rebelo M, Tang C, Coelho AR, Labão-Almeida C, Schneider MM, Tatalick L, Ruivo P, de Miranda MP, Gomes A, Carvalho T, Walker MJ, Ausserwoeger H, Pedro Simas J, Veldhoen M, Knowles TPJ, Silva DA, Shoultz D, Bernardes GJL

Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016.
(2018 Nov)
Lancet Infect Dis 18(11): 1229-1240
Khalil IA, Troeger C, Blacker BF, Rao PC, Brown A, Atherly DE, Brewer TG, Engmann CM, Houpt ER, Kang G, Kotloff KL, Levine MM, Luby SP, MacLennan CA, Pan WK, Pavlinac PB, Platts-Mills JA, Qadri F, Riddle MS, Ryan ET, Shoultz DA, Steele AD, Walson JL, Sanders JW, Mokdad AH, Murray CJL, Hay SI, Reiner RC Jr

Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses study.
(2018 Jul)
Lancet Glob Health 6(7): e758-e768
Khalil IA, Troeger C, Rao PC, Blacker BF, Brown A, Brewer TG, Colombara DV, De Hostos EL, Engmann C, Guerrant RL, Haque R, Houpt ER, Kang G, Korpe PS, Kotloff KL, Lima AAM, Petri WA Jr, Platts-Mills JA, Shoultz DA, Forouzanfar MH, Hay SI, Reiner RC Jr, Mokdad AH

Pediatric cryptosporidiosis: An evaluation of health care and societal costs in Peru, Bangladesh and Kenya.
(2017)
PLoS One 12(8): e0182820
Rafferty ER, Schurer JM, Arndt MB, Choy RKM, de Hostos EL, Shoultz D, Farag M

Show complete publication list